Table 6. Therapeutic indices (T.I.) of [K³]SHa and SHa^a.

T.I.b	Human	THP1-	THP1-derived	HepG2	Fibroblasts
[K3]SHa (SHa)	erythrocytes	monocytes	macrophages
Gram-negative strains	13.1 (1.7)	12.6 (8.3)	14.5 (4.2)	94.2 (38.9)	52.6 (13.9)
	7.70c	1.52	3.45	2.42	3.78
Gram-positive strains	17.8 (4.2)	17.1 (20)	19.6 (10)	127.8 (93.3)	71.4 (33.3)
	4.24	0.85	1.96	1.37	2.14
Yeast/fungal strains	6.5 (0.8)	6.2 (3.8)	7.1 (1.9)	46.5 (18)	26 (6.4)
	8.12	1.63	3.37	2.58	4.06

^a Therapeutic indices of SHa are indicated in parentheses.

^b Ratio of IC₅₀ or LC₅₀ values (for human cells from Table 5) over the geometric mean of MIC values (from Table 3 and corresponding to Gram-negative, Gram-positive, and yeast/fungal strains). When IC₅₀ or LC₅₀ values were higher than the maximum concentration tested, a minimal 2-fold concentration value was used to calculate the therapeutic index because IC₅₀ or LC₅₀ values were determined by carrying out serial 2-fold dilutions (for example, LC₅₀ > 100 was considered as 200).

^c Values in bold represent the fold improvement in the therapeutic index of [K³]SHa compared to SHa.